Skip to main content
. Author manuscript; available in PMC: 2016 Nov 24.
Published in final edited form as: ACS Nano. 2015 Oct 12;9(11):10695–10718. doi: 10.1021/acsnano.5b05974

Figure 1.

Figure 1

Overall design of re-purposed therapeutics. (A) Design of bexarotene prodrug and its chemical components; (B) layered arrangement of bexarotene-prodrug after self-assembling into a gas-filled bubble followed by its rupture upon US exposure; (C) prodrug interacts favorably with the cancer cell membrane to get inserted and eventually be cleaved enzymatically releasing the active pharmaceutical ingredient.